Plasmid-mediated 16S rRNA methylases among extended-spectrum-b-lactamase-producing Salmonella enterica Senftenberg isolates from Algeria Thierry Naas 1 *, Chafia Bentchouala 2 , Sandra Lima 1 , Abdesselam Lezzar 2 , Farida Smati 2 , Jean-Michel Scheftel 3 and Patrice Nordmann 1 1 INSERM U914: 'Emerging Resistance to Antibiotics', Service de Bactériologie -Virologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, Assistance Publique/Hôpitaux de Paris, Faculté de Médecine Paris-Sud, 94275 Le Kremlin-Bicêtre, France; 2 Service de Microbiologie, Centre Hospitalier Universitaire, Constantine, Algeria; 3 Laboratoire de Bactériologie des Hôpitaux Universitaire de Strasbourg, France Keywords: ESBLs, nosocomial, CTX-M-3, ArmA *Corresponding author. Tel: þ33-1-45-21-29-86; Fax: þ33-1-45-21-63-40; E-mail: thierry.naas@bct.ap-hop-paris.fr Sir, High levels of resistance to aminoglycosides conferred by plasmid-mediated mechanisms corresponding to 16S rRNA methylases have been reported since 2003. 1 To date, six enzymes (ArmA, RmtA, RmtB, RmtC, RmtD and NpmA) are known, with ArmA being the most frequently identified methylase in Enterobacteriaceae. 2 Associations between 16S rRNA methylaseand extended-spectrum b-lactamase (ESBL)-encoding genes such as the bla CTX-M genes have been reported. 2, 3 In 2004, an outbreak of CTX-M-producing Salmonella enterica serotype Senftenberg isolates associated with nosocomial diarrhoea in newborns was described in the neonatology unit at the university hospital of Constantine, Algeria. 4 These isolates remained susceptible to imipenem, ertapenem, cefoxitin, nalidixic acid, fluoroquinolones and colistin only. 4 The aim of this study was to evaluate the prevalence of 16S rRNA methylase genes among representative ESBL-producing S. enterica Senftenberg isolates resistant to aminoglycosides recovered in the neonatology ward from January 1982 to December 2005. In total, 12 non-duplicate ESBL-producing S. enterica serotype Senftenberg clinical isolates, expressing variable levels of resistance to aminoglycosides, were studied. The isolates were screened by PCR for detection of 16S rRNA methylase-encoding genes (armA, rmtA, rmtB, rmtC, rmtD and npmA), as previously described. 2 Among them, one isolate from 1998 was resistant to all clinically used aminoglycosides and was found to be positive for armA. The other isolates were all negative for all of the tested 16S RNA methylase genes and presented variable levels of resistance to the clinically used aminoglycosides. PCR experiments with primers for detection of the Ambler class A bla TEM , bla SHV , bla PER-1/2 , bla VEB-1 , bla GES-1 and bla CTX-M genes, followed by sequencing, identified two b-lactamases in the armA-positive isolate: TEM-1 and the ESBL CTX-M-3. 4 The 16S rRNA methylase and ESBL determinant were co-transferred by conjugation and transformation using Escherichia coli J53 and TOP10 recipient strains after selection on trypticase soy agar containing amikacin (50 mg/L) and/or ticarcillin (50 mg/L). 4 The 16S rRNA methylase-positive transformants and transconjugants displayed the same antimicrobial resistance profile and expressed a high level of resistance to aminoglycosides ( Table 1 ). The armA and bla CTX-M-3 genes were located on the same plasmid belonging to the IncL/M incompatibility group, as observed for plasmid pCTX-M-3. 5 Sequencing of the 16S rRNA methylase-encoding genes showed perfect identity with previously reported genes. PCR mapping of the region containing the armA gene showed its association with ISCR1 inside a sul1-type integron structure, the same configuration as observed in Tn1548. 6 This is the first report of an Arm-type 16S rRNA methylase enzyme in Algeria and from S. enterica serotype Senftenberg. This study demonstrates that the association on the same plasmid of 16S rRNA methylase-and CTX-M-3-encoding genes can be found in Salmonella isolates as early as 1998, i.e. 3 years before its initial discovery. Their localization on the same conjugative plasmid is worrying since it has the potential to further expand the threat of multidrug-resistant Salmonella. Spread of these aminoglycoside resistance determinants at the same level as bla CTX-M genes in Enterobacteriaceae may seriously compromise the efficacy of aminoglycosides for treating Gram-negative infections. A more extensive study is now required to investigate the prevalence of these methylases in Salmonella isolates from Algeria. The prevalence rate of 16S rRNA methylase determinants among ESBL producers is still generally low, ranging from 0.03% in Japan to 3% in Korea, but may be as high as 10% in China. 2, 3, 7 This work further underlines that Salmonella may be a reservoir for ESBL genes but also for 16S rRNA methylase genes in the community, and that these strains may then be responsible for hospital-acquired infections.
Transparency declarations
None to declare. 1 The emergence of such strains with concomitant vancomycin therapeutic failures 2 has necessitated the development of other therapeutic agents. Newer drugs of the glycopeptide class, such as oritavancin, with activity against isolates with reduced susceptibility to vancomycin are currently in development. Additional mechanisms exhibited by oritavancin help explain its rapid, concentration-dependent bactericidal activity in vitro 3 and distinguish it from vancomycin.
In surveillance studies, oritavancin activity was demonstrated against vancomycin-susceptible S. aureus isolates that are susceptible and resistant to methicillin. 4 This study examined the in vitro activity of oritavancin against clinical isolates of VRSA, VISA and hVISA using recently updated broth microdilution methodology. 5 MICs and MBCs of oritavancin were determined for these groups of organisms and compared with those of seven clinically used antimicrobial agents.
MICs of antimicrobial agents were determined by broth microdilution according to CLSI (formerly NCCLS) guidelines. 5 Polysorbate-80 was included when testing oritavancin, so as to limit losses of oritavancin to the surfaces of test vessels as recommended in CLSI guidelines. 5 MBCs were also determined according to CLSI guidelines. 6 Aliquots (50 mL) were plated onto brain heart infusion agar (BHIA) plates for the VISA and hVISA isolates, or BHIA plates containing 4 mg/L vancomycin for the VRSA isolates to maintain selection for vancomycin, and incubated at 358C for 24 h. The MBC was defined as the lowest concentration killing .99.9% of the original inoculum. 6 Oritavancin showed good in vitro activity against the hVISA isolates (MIC range of 0.12 -2 mg/L and MIC 90 of 1 mg/L; Table 1 ). The oritavancin MIC 90 was identical to those of linezolid and quinupristin/dalfopristin, and one doubling dilution higher than that of tigecycline. The oritavancin MIC 90 was 2-to 8-fold lower than those of the rest of the comparators. The oritavancin MBC range and MBC 90 against hVISAs were 0.25 -2 and 1 mg/L, respectively. The oritavancin MBC 90 against the hVISA isolates was identical to that of tigecycline and 2-to 64-fold lower than those of the rest of the comparators. The oritavancin MBC 90 /MIC 90 ratio of 1 indicates that oritavancin is bactericidal against hVISA. The oritavancin MBC 90 /MIC 90 ratio was identical to that of daptomycin and 2-to 16-fold lower than those of the rest of the comparators.
Oritavancin showed good in vitro activity against the VISA isolates (MIC range of 0.5 -4 mg/L and MIC 90 of 2 mg/L; Table 1 ). The MIC 90 was identical to that of quinupristin/dalfopristin and was two doubling dilutions higher than that of tigecycline. The oritavancin MIC 90 was 2-to 8-fold lower than those of the rest of the comparators. The oritavancin MBC range and MBC 90 against VISAs were 0.5 -8 and 4 mg/L, respectively. The oritavancin MBC 90 for the VISA isolates was 4-fold higher than that of tigecycline and 2-to 8-fold lower than those of the rest of the comparators. The oritavancin MBC 90 /MIC 90 ratio of 2 indicates that oritavancin is bactericidal against VISA. The oritavancin MBC 90 /MIC 90 ratio was identical to, or within a dilution of, those of the comparators.
Oritavancin showed good in vitro activity against the VRSA isolates (MIC range of 0.12 -1 mg/L and MIC 90 of 0.5 mg/L; Table 1 ). The MIC 90 was identical to that of daptomycin and was a doubling dilution higher than that of tigecycline. The oritavancin MIC 90 was 2-to .1024-fold lower than those of the rest of the comparators. The oritavancin MBC range and MBC 90 against VRSAs were 0.25-1 and 1 mg/L, respectively. The oritavancin MBC 90 for the VRSA isolates was 2-to .512-fold lower than those of the comparators. The oritavancin MBC 90 /MIC 90 ratio of 2 indicates that oritavancin is bactericidal against VRSA. The oritavancin MBC 90 /MIC 90 ratio was at least 2-fold lower than those of the comparators.
Against the 35 isolates of S. aureus tested in this study, the oritavancin MIC range and MIC 90 were 0.12-4 and 1 mg/L, respectively ( Table 1 ). The oritavancin MIC 90 was identical to that of quinupristin/dalfopristin and was a doubling dilution
